Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 03:00PM GMT
Release Date Price: €28.75 (+4.17%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Good morning. Welcome to Day 2 of the Bank of America Healthcare conference. I'm Tazeen Ahmad. I'm one of the senior SMID biotech analyst here at Bank. It's my pleasure to have our next presenting company here with us, Sage Therapeutics. Sitting with me this morning will be Alan Chris. I'll let you guys introduce yourselves, and maybe, Chris, you could give us an overview -- a quick 2-minute overview of what's been happening at Sage Therapeutics.

Christopher Benecchi
Sage Therapeutics, Inc. - Chief Commercial Officer

Sure. I'm Chris Benecchi. I'm the Chief Commercial Officer at Sage. We show the Chief Scientific Officer of Sage Therapeutics. So first of all, Tazeen, thanks for having us. It's an exciting, and it's great to be here. It's an exciting time to be a part of Sage, and we're off to an incredibly strong start in 2022.

When you take a step back and think about what we've already accomplished -- with respect to clinical development, we are planning

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot